Endothelin-1 and endothelial nitric oxide polymorphisms in idiopathic pulmonary arterial hypertension

International Journal of Molecular Epidemiology and Genetics

Volumn 1, Issue 3, 2010, Pages 208-213

  Vadapalli, Shivani ^a   Surekha Rani, H ^a   Sastry, B K S ^b   Nallari, Pratibha ^a  

^a OSMANIA UNIVERSITY   (India)

^b CARE HOSPITAL   (India)

Author keywords

EDN1; Endothelial dysfunction; IPAH; Linkage disequilibrium; NOS3; Polymorphism

Indexed keywords

ASPARAGINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; LYSINE; NITRIC OXIDE;

ADULT; ARTICLE; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; HUMAN; IDIOPATHIC PULMONARY HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PULMONARY HYPERTENSION;

EID: 77955702459     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003;42:1149-1160.
2. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
3. Gaine S: Pulmonary hypertension. JAMA 2000; 284: 3160-3168.
4. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, Levy PS, Pietra GG, Reid LM, Reeves JT, Rich S, Vreim CE, Williams GW and Wu M. Survival in patients with primary pulmonary hypertension - results from a national prospective registry. Ann Intern Med 1991;115:343-349.
5. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, Nichols WC. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-ß family. J. Med Genet. 2000; 37:741-745
6. Hoeper MM, Faulenbach C, Golpon H, Winkler J., Welte T. Niedermeyer J: Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Eur Respir J 2004; 24: 1007-1010.
7. Gruenig E, Michelakis E, Vachiéry JL, Vizza CD, Meyer FJ, Doelberg M, Bach D, Dingemanse J, Galiè N. Acute Hemodynamic Effects of Single- Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASS-1 Study. J Clin Pharmacol. 2009;49(11):1343-52.
8. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK et al: Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107,216-223
9. Lahari D and Nurunberger JA. Rapid nonenzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic acids Res. 1991;19:5444
10. Algovik M, Lagercrantz J, Westgren M, Nordenskjold A. No mutations found in candidate genes for dystocia. Hum Reprod 1999;14(10): 2451-2454.
11. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphism. Proc Natl Acad Sci USA 1989; 86:2766-70
12. Sim AS, Wang J, Wilcken D, Wang XL. MspI polymorphism in the promoter of the human endothelial constitutive NO synthase gene in Australian Caucasian population. Mol Genet Metab 1998;65:62.
13. Cai H, Wilcken DE, Wang XL. The Glu-298 → Asp (894G → T) mutation at exon 7 of the endothelial nitric oxide synthase gene and coronary artery disease. J Mol Med 1999; 77:511-514.
14. Sujana K, Sastry BKS, Nallari P. Endothelin 1. A vasoconstrictor in primary pulmonary hypertension. J Cell Tiss Res 2007;7(1):867-870.
15. Stewart, DJ, Levy, RD, Cernacek, P et al: Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-469.
16. Giaid A, and Saleh D. Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension. N Engl J Med 1995;333(4):214-221.
17. Nootens M, Kaufmann E, Rector T, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995;26:1581-1585.
18. Rubens C, Ewert, R, Halank, M, Wensel, R, Orzechowski, HD, Schultheiss, HP, and Hoeffken G, M: Big Endothelin-1 and Endothelin-1 Plasma Levels Are Correlated With the Severity of Primary Pulmonary Hypertension. Chest 2001;120 (5):1562-1569.
19. Popowski K, Sperker B, Kroemer HK, John U, Laule M, Stangl K: Functional significance of a hereditary adenine insertion variant in the 5'- UTR of the endothelin-1 gene. Pharmacogenet 2003;13:445-451.
20. Tanaka C, Kamide K, Takiuchi S, Kawano Y, Miyata T: Evaluation of the Lys198Asn and -134delA genetic polymorphisms of the endothelin-1 gene. Hypertens Res 2004;27(5):367-71.
21. Sorrentino S, Forleo C, Iacoviello M, Guida P, D'Andria V, Favale S. Endothelin system polymorphisms in tilt test-induced vasovagal syncope. Clin Auton Res 2009, 19 (6); 347-354.
22. Rajput C, Najib S, Norboo T, Afrin F, Qadar PMA. Endothelin-1 gene variants and levels associate with adaptation to hypobaric hypoxia in highaltitude natives: Biochem Biophys Res Commun 2006;341(4):1218-1224.
23. Lee J, Cheong S, Kim J. Association of endothelin-1 gene polymorphisms with variant angina in Korean patients. Clin Chem Lab Med 2008; 46(11):1575-1580.
24. Taylor MRG, Slavov D, Humphrey K, Lan Z, Cockroft J, Xiao Z, Lavori P, Bristow MR, Mestroni L, Lazzeroni LC. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics 2009;19(1):35-43.
25. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, Motoyama T, Saito Y, Ogawa Y, Miyamoto Y, Nakao K. T-786->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circ 1999; 99:2864-2870.
26. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A 2000;97(6):2832-5.
27. Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, Voelkel NF. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004;169(6):764-9.